summari ew report underli revenu
underli beat consensu
estim adj ep also came ahead
consensu estim ew underli
global thv transcathet heart valv sale
underli fell short consensu expect
respect thv growth
repres meaning deceler vs growth
deceler primarili driven competit dynam europ
tough y/i compar pipelin front
notabl develop view trial
centera expect begin cap continu
access protocol expect initi harpoon
implant paus due complic earli patient
term outlook ew expect underli sale growth
vs continu expect sale come
toward higher-end report rang
bottom line ew increas adj ep guidanc
report ew guid total sale
report adj ep
report
view quarter disappoint given perform
thv particularli europ remain bullish stock given
upcom opportun low-risk robust ew pipelin wed
note current model ew underli sale growth
modestli ew guidanc includ
underli thv growth reflect conservat
estim chang lower sale estim
underli rais adj ep
estim report rais
sale estim report
adj ep estim report maintain
price target assum adj
continu next page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
compani prioriti stock list
compani data secur llc estim reuter
top-lin tavr miss underli ww thv sale came
street expect discuss compani recent investor dayew
longer provid break-out us ou thv sale regard us manag said procedur
growth market roughli line ew growth mid-teen ou outsid us
manag said ew procedur growth low double-digit europ specif ew note
procedur growth broader market grew double-digit due share loss
base compani commentari estim ew us thv sale vs
previou estim estim ew ou thv sale underli vs
previou estim estim ew thv sale europ
japan respect get insight ou market dynam report
earn may ew re-affirmed full-year thv guidanc higher-end
dollar rang higher-end underli growth guidanc impli
acceler throughout year
 trial centera schedul start ultra still expect receiv approv
us/europ call ew announc receiv fda approv begin us pivot trial
centera enrol expect begin manag note single-arm trial includ
nearli intermedi risk patient month primari endpoint trial includ roll-in
patient also bicuspid sub-studi ou ew said earli target launch centera europ gone
well clinician feedback positivethough sale contribut quarter minim
separ sapien ultra ew continu expect ce mark fda approv late
ew process conduct small clinic trial support european regulatori
submiss manag wouldnt comment potenti data requir requir fda
approv
continu access protocol cap announc ew announc approv cap
low-risk trial previous complet enrol cap includ limit
number low-risk patient select clinic site cap expect begin
make rel modest contribut sale manag expect cap contribut less
thv growth ew continu expect present data american
colleg cardiolog march low risk indic late
transcathet mitral tricuspid updat regard commerci activ ew record cardioband
mr sale less manag said encourag high procedur success
rate ew still expect tmtt transcathet mitral tricuspid program ramp throughout year
contribut sale worth mention cardioband still integr
ew qualiti system could lead inventori constraint year addit manag
provid sever updat transcathet mitral tricuspid program notabl updat
follow harpoon ce mark approv implant paus complic aris
patient earli clinic studi pascal clasp ce mark trial expect finish enrol
put launch time track us pascal studi schedul begin
cardioband tr european approv still anticip year-end site continu activ
us earli feasibl studi regard tmvr transcathet mitral valv replac program
cardiaq sapien ew note pleas progress devic
shv growth driven replac intuiti elit inspiri ew report shv surgic
heart valv sale underli beat consensu estim
result driven mid-single-digit underli heart valv sale growth versu mid-
single-digit declin compani smaller repair segment manag note strength
behind intuiti elit strong clinician demand ew latest shv inspiri resilia manag still
expect launch inspiri japan later year provid japanes reimburs place ew
re-affirmed underli growth expect shv busi continu
expect shv sale come toward higher-end rang
momentum critic continu ew report critic cc sale
underli beat consensu estim respect result
quarter driven strong broad base growth across busi particular strength
apac region manag continu view hemospher advanc monitor platform
import growth driver long-term note posit continu feedback clinician
given momentum busi ew expect critic care underli growth come
higher end rang manag continu expect cc sale higher-end
outlook rais guidanc introduc call ew rais underli sale
growth outlook manag continu expect total sale come
toward higher-end guidanc rang bottom-lin adj ep guidanc
increas report impact sale fx expect
tailwind previous busi manag continu expect
sale dollar basi high-end previou guidanc rang thv ew expect
sale higher-end dollar rang higher-end underli growth
guidanc ew expect shv sale higher-end rang underli cc
come higher-end rang higher-end underli guidanc
move ew reiter guidanc item gross margin
sg dilut share count notabl ew lower tax rate
guidanc due favor expect benefit tax reform
higher sbc relat deduct ew guid total sale
report adj ep report
price target nc
price target assum ep estim risk includ greater
share loss model delay mitral program neg clinic data
believ upcom data pipelin product help ew address new competit
transcathet mitral valv opportun signific catalyst
irvin california -base edward lifesci ew develop manufactur market product
design heart valv diseas cardiac surgeri critic care edward revenu reach
billion come transcathet heart valv therapi thv busi ew
player transcathet heart valv therapi market
edward lifesci -- quarterli incom statementin million except per share dataproduct line good sold excl gross gross oper oper oper expens expens incom pre-tax net dilut share amort expens exclud share count forward adjust two-for-on stock splitsourc compani report secur llc estim edward lifesci corpor
